Predict your next investment

Corporation
kyowakirin.co.jp

See what CB Insights has to offer

Investments

3

Portfolio Exits

2

Partners & Customers

10

About Kyowa Kirin

Kyowa Kirin is a global specialty pharmaceutical company based in Japan. They focus on the anti-body technologies in the core therapeutic areas of oncology, nephrology, and immunology.

Kyowa Kirin Headquarter Location

9-2 Otemachi Chiyoda Ward Otemachi Financial City Grand Cube

Tokyo, 100-0004,

Japan

03-5205-7200

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Kyowa Kirin News

Kyowa Kirin expands Inveniai AI platform collaboration once again

Jan 11, 2022

Jan. 10, 2022 Inveniai LLC and Kyowa Kirin Co. Ltd. have expanded their partnership a second time, inking their most recent multiple drug discovery agreement. The multiyear deal will see the duo discover novel targets and treatments for therapeutic areas across Kyowa Kirin’s portfolio and areas of interest using Inveniai’s artificial intelligence (AI) platform.

Kyowa Kirin Investments

3 Investments

Kyowa Kirin has made 3 investments. Their latest investment was in Ardelyx as part of their Corporate Minority - P2P on November 11, 2019.

CBI Logo

Kyowa Kirin Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/26/2019

Corporate Minority - P2P

Ardelyx

$20M

Yes

8

1/11/2010

Partnership

Subscribe to see more

$99M

Subscribe to see more

0

9/23/2007

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/26/2019

1/11/2010

9/23/2007

Round

Corporate Minority - P2P

Partnership

Series A - II

Company

Ardelyx

Subscribe to see more

Subscribe to see more

Amount

$20M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

8

0

10

Kyowa Kirin Portfolio Exits

2 Portfolio Exits

Kyowa Kirin has 2 portfolio exits. Their latest portfolio exit was Solasia Pharma on March 23, 2017.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/23/2017

IPO

1

1/30/2014

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/23/2017

1/30/2014

Exit

IPO

IPO

Companies

Subscribe to see more

Valuation

$99M

Acquirer

Subscribe to see more

Sources

1

10

Kyowa Kirin Acquisitions

1 Acquisition

Kyowa Kirin acquired 1 company. Their latest acquisition was Archimedes Pharma on July 11, 2014.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/11/2014

$99M

Acquired

1

Date

7/11/2014

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acquired

Sources

1

Kyowa Kirin Partners & Customers

10 Partners and customers

Kyowa Kirin has 10 strategic partners and customers. Kyowa Kirin recently partnered with Generis on October 10, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

10/8/2021

Vendor

Generis

United States

Japanese Pharmaceutical Group Kyowa Kirin Selects the Generis CARA™ Life Science Platform for Global Regulatory Correspondence Management

Commenting on the partnership , James Kelleher , CEO of Generis , said , `` We are delighted to have the opportunity to work with Kyowa Kirin to bring their products to market using the CARA to ensure consistent Health Authority communications while reducing the burden of day-to-day operations . ''

1

8/4/2021

Licensor

SynAffix

Netherlands

Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline

Under the terms of the agreement , upon exercise of an option by Kyowa Kirin for further development and commercialisation of such selected ADC target , Synaffix is eligible to receive a license issuance fee for each additional target and milestone payments plus royalties on potential future commercial sales of ADCs developed against each licensed target .

2

7/9/2021

Licensor

AM-Pharma

Netherlands

Ysios Capital portfolio company AM-Pharma and Kyowa Kirin sign exclusive license agreement for commercialization of Ilofotase alfa in Japan

`` As an organization centered around research , development and partnerships with innovative drug discovery organizations around the globe , we are excited to initiate this relationship with AM-Pharma B.V. to potentially improve the lives of patients and families affected by sepsis-associated acute kidney injury , '' added Tomohiro Sudo , Executive Officer , Head of Global Product Strategy Department at Kyowa Kirin .

2

6/1/2021

Partner

Amgen

United States

Subscribe to see more

Subscribe to see more

10

4/16/2021

Partner

Ardelyx

United States

Subscribe to see more

Subscribe to see more

10

Date

10/8/2021

8/4/2021

7/9/2021

6/1/2021

4/16/2021

Type

Vendor

Licensor

Licensor

Partner

Partner

Business Partner

Generis

SynAffix

AM-Pharma

Amgen

Ardelyx

Country

United States

Netherlands

Netherlands

United States

United States

News Snippet

Japanese Pharmaceutical Group Kyowa Kirin Selects the Generis CARA™ Life Science Platform for Global Regulatory Correspondence Management

Commenting on the partnership , James Kelleher , CEO of Generis , said , `` We are delighted to have the opportunity to work with Kyowa Kirin to bring their products to market using the CARA to ensure consistent Health Authority communications while reducing the burden of day-to-day operations . ''

Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline

Under the terms of the agreement , upon exercise of an option by Kyowa Kirin for further development and commercialisation of such selected ADC target , Synaffix is eligible to receive a license issuance fee for each additional target and milestone payments plus royalties on potential future commercial sales of ADCs developed against each licensed target .

Ysios Capital portfolio company AM-Pharma and Kyowa Kirin sign exclusive license agreement for commercialization of Ilofotase alfa in Japan

`` As an organization centered around research , development and partnerships with innovative drug discovery organizations around the globe , we are excited to initiate this relationship with AM-Pharma B.V. to potentially improve the lives of patients and families affected by sepsis-associated acute kidney injury , '' added Tomohiro Sudo , Executive Officer , Head of Global Product Strategy Department at Kyowa Kirin .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

2

2

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.